Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;2010:251208.
doi: 10.1155/2010/251208. Epub 2010 Dec 1.

Comorbidity-adjusted Survival in Early Stage Lung Cancer Patients Treated With Hypofractionated Proton Therapy

Affiliations
Free PMC article

Comorbidity-adjusted Survival in Early Stage Lung Cancer Patients Treated With Hypofractionated Proton Therapy

Sharon Y Do et al. J Oncol. .
Free PMC article

Abstract

Objective. To determine the influence of comorbidity on survival in early-stage lung cancer patients treated with proton radiotherapy, using the Charlson Comorbidity Index. Study Design and Setting. Fifty-four non-small-cell lung cancer patients, treated prospectively in a phase II clinical trial with hypofractionated proton therapy, were analyzed retrospectively to assess their burden of comorbid disease as expressed by Charlson Comorbidity Index. Using the Charlson Comorbidity Index method, a predicted survival curve based on comorbidity was formulated and compared to the observed mortality from causes other than lung cancer in the study population. Results. The study population had an average age score of 2.8 and an average Charlson Comorbidity Index of 4.7. Predicted survival was calculated to be 67% and 50% at 2 and 4 years, respectively. Actual comorbidity-specific survival at 2 and 4 years was 64% and 45%, respectively. The observed survival fell within the 95% confidence intervals of the predicted survival at all time points up to 5 years. Conclusion. Predicted mortality from concurrent disease, based on Charlson Comorbidity Index, correlated well with observed comorbidity-specific mortality. This helps substantiate the accuracy of the data coding in cause of death and strengthens previously reported disease-specific survival rates.

Figures

Figure 1
Figure 1
(a) Representative treatment plan. Colored contour lines indicate percentage of total dose given. (b) Dose-volume histogram showing doses given to volumes of tumor (red) and lung (green).
Figure 2
Figure 2
Survival curves showing actual comorbidity-specific survival and predicted survival, with 95% confidence intervals.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. American Cancer Society. October 2008, http://www.cancer.org/Cancer/LungCancer-SmallCell/OverviewGuide/lung-cancer-small-cell-overview-key-statistics.
    1. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase II study. International Journal of Radiation Oncology Biology Physics. 2009;75(3):677–682. - PubMed
    1. Salazar OM, Sandhu TS, Lattin PB, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced and 7 metastatic lung cancers. International Journal of Radiation Oncology Biology Physics. 2008;72(3):707–715. - PubMed
    1. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. International Journal of Radiation Oncology Biology Physics. 2001;51(3):666–670. - PubMed
    1. Charlson ME, Pompei P, Ales KA, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987;40(5):373–383. - PubMed

LinkOut - more resources

Feedback